ライフサイエンスコーパス: CD40

1 CD40 agonists bind the CD40 molecule on antigen-presenti

2 CD40 deficiency impairs this process and prevents diabet

3 CD40 is a costimulatory receptor on APCs that is critica

4 CD40 ligand (CD40L) deficiency predisposes to opportunis

5 CD40 ligand (CD40L) deficiency, an X-linked primary immu

6 CD40 ligand (CD40L), a member of the tumor necrosis fact

7 CD40 ligand- and Toll-like receptor 9-mediated signaling

8 CD40 ligation in Muller cells triggered phospholipase C-

9 CD40 occupancy by iscalimab prevented ex vivo human rCD1

10 CD40 plays an important role in immune responses by acti

11 CD40 signaling can further revert myeloid cell different

12 CD40 upregulation, IL-6 production, growth in response t

13 CD40, a member of the tumour necrosis factor receptor (T

14 tory molecule cluster of differentiation 40 (CD40) in Muller glia has been implicated in the initiati

15 R T cells and cluster of differentiation 40 (CD40), could also enhance CAR T cell activity and mediat

16 s identify a PPARgamma-dependent miR-424/503-CD40 signaling axis that is critical for regulation of i

17 Complete (>=90%) CD40 receptor occupancy on whole blood B cells was obser

18 e dual secretion of IL-21 and IFN-gamma in a CD40/CD40L-dependent manner.

19 mmatory responses in myeloid cells through a CD40-ATP-P2X7 pathway.

20 Thus, a CD40 antagonist Ab could be an effective therapeutic in

21 Treatment with a CD40 agonist antibody preferentially activated a cDC pop

22 lated surface expression of HLA-DR, HLA-ABC, CD40, CD80, CD83, and CD86, induced naive alphabeta T-ce

23 Accordingly, CD40 and its ligand, CD40L, have long been considered ta

24 Here, the effects of constitutively active CD40 in DCs on atherosclerosis were examined using low-d

25 percentages of B cells producing IL-10 after CD40 ligation and higher expression of CD40L on activate

26 function as a competitive antagonist against CD40 activation.

27 omposite vaccination, including an agonistic CD40 antibody, soluble antigen, and a TLR3 agonist, refe

28 production by B cells was due to an altered CD40 and/or BCR signalling.

29 IL-6 (p = 0.002), MIP-3alpha (p = 0.02) and CD40-L levels (p = 0.002) significantly increased from 5

30 and differs from TNFalpha, Interleukin-1 and CD40 signaling.

31 T2/IL-1R4; and decreased levels of IL-13 and CD40 were found in all flavivirus group samples, compare

32 ressing interferon-gamma, interleukin-2, and CD40 ligand) responses were evaluated at month 6.5 for a

33 effects were mediated primarily by IL-21 and CD40 signaling, leading to the upregulation of tolerogen

34 g cells obtained by Toll-like receptor 9 and CD40 activation of B cells prevented TFH cell developmen

35 Integrin alpha5beta1 and CD40 simultaneously bind to CD40L.

36 It is unclear if alpha5beta1 and CD40 work together in CD40/CD40L signaling or how alpha5

37 tform characterized by in vivo amplified and CD40-mediated specific responses to generate MERS-CoV S1

38 ts were isolated from blood of apoE(-/-) and CD40(-/-)apoE(-/-) mice, respectively.

39 ound unique cellular requirements for B7 and CD40 expression in primary GC responses to vaccine immun

40 t, no requirement for coexpression of B7 and CD40 on the same cell in these responses.

41 itic cells (DCs), in the presence of B7- and CD40-dependent co-stimulatory pathways.

42 rucial and distinct contributions of B7- and CD40-dependent pathways expressed by different APC popul

43 n response to engagement of both the BCR and CD40 or strong cross-linking of CD40 alone.

44 Akt/S6 kinase signaling pathway upon BCR and CD40 stimulation.

45 B cell antigen receptor (BCR) and CD40 signaling are rewired in germinal center (GC) B cel

46 e to combinations of checkpoint blockers and CD40 agonists.

47 he expression of the B cell markers CD23 and CD40, which are important for B cell differentiation int

48 amma induces HLA class II, HLA-DM, CD80, and CD40 expression on MCs, whereas MCs take up soluble and

49 Ag presentation on MHC I molecules, CD86 and CD40 expression, and the production of IL-12 p70, IL-2,

50 the costimulatory molecules CD80, CD86, and CD40.

51 MHC-II expression and CD40 expression in pulmonary CD11b(+) DCs were markedly

52 , IDO1, LAG3, TIM3, ICOSLG, VISTA, GITR, and CD40 in formalin-fixed, paraffin-embedded (FFPE) NSCLC s

53 at their emergence required MHC class II and CD40/CD40L interactions.

54 e for cognate CD4(+) T cell interactions and CD40 signalling in cDC1 licensing.

55 VEGF, TIMP3, TIMP4, MMP13, ITGA2, ITGA3 and CD40, which promoted collagen synthesis, deposition and

56 with the cognate receptors, CD137 ligand and CD40 initiates activation of nuclear factor-kappa B (NF-

57 ding lymphotoxin-beta receptor (LTbetaR) and CD40.

58 pression and an increase in iNOS, MHCII, and CD40 expression.

59 Levels of beta-2 microglobulin and CD40 antigen and presence of hepatitis C virus (HCV) inf

60 proteins, including beta-2 microglobulin and CD40, correlated with GFR changes over the first year.

61 t and inhibitors of B7-related molecules and CD40, blockade of B cell function and B cell survival fa

62 BCR, B cell-activating factor receptor, and CD40 coreceptor programs, leading to broadly enhanced po

63 Wild-type and CD40-deficient platelets were isolated from blood of apo

64 ap formation, but involves GPIbalpha-vWF and CD40-CD40L-dependent platelet interactions.

65 Anti-CD40 monoclonal antibodies (mAbs) comprise agonists and

66 Anti-CD40 treatment also prevented and reversed loss of saliv

67 Anti-CD40/CpG + IC/anti-CTLA-4 synergistically induced regres

68 tion of omalizumab did not enhance IL-4/anti-CD40-induced IgE production in vitro.

69 of omalizumab on IgE production by IL-4/anti-CD40-treated PBMCs from allergic patients were studied i

70 ouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also b

71 ously shown the synergy of an agonistic anti-CD40 mAb (anti-CD40) and CpG-oligodeoxynucleotides in ac

72 e interact to deliver optimal agonistic anti-CD40 mAbs.

73 an previously reported highly agonistic anti-CD40 mAbs.

74 -1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumour-associat

75 We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangio

76 ies collected from monkey dosed with an anti-CD40 antibody.

77 CD154 costimulation pathway, such as an anti-CD40 mAb, suppresses the adaptive immune response, leadi

78 ted disease expression in a model of an anti-CD40-induced hyperinflammatory syndrome with necrotic he

79 by soluble DR3 ameliorates both DSS and anti-CD40 antibody-induced colitis.

80 he other hand, both anti-VEGFA/Ang2 and anti-CD40 independently promoted proinflammatory macrophage s

81 reated with bortezomib, belatacept, and anti-CD40 mAb twice weekly for a month (n = 6) and compared t

82 Both DSS and anti-CD40 models exhibited liver inflammation associated with

83 using dextran sulfate sodium (DSS) and anti-CD40 murine colitis models in response to interleukin-22

84 using dextran sulfate sodium (DSS) and anti-CD40-induced colitis models.

85 e cultured tonsil B cells with IL-4 and anti-CD40.

86 rt-term immunotherapy with antagonistic anti-CD40 antibody 2C10R4, rapamycin, soluble tumor necrosis

87 st immunization via NYVAC-KC and either anti-CD40.Env gp140/poly-ICLC or anti-LOX-1.Env gp140/poly-IC

88 Immunologically, anti-CD40 treatment disrupted multiple processes that contrib

89 synergy of an agonistic anti-CD40 mAb (anti-CD40) and CpG-oligodeoxynucleotides in activating macrop

90 o antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement

91 We suggest that a combination of anti-CD40/CpG and IC/anti-CTLA-4 should be developed for clin

92 Although the antitumor effect of anti-CD40/CpG did not require T cells, the antitumor effect o

93 cation (RCA) products that are based on anti-CD40 DNA aptamers as a novel vaccine adjuvant.

94 We recently reported anti-CD40 monoclonal antibody and rapamycin (aCD40/rapa) to b

95 GD2(+) B78 melanoma model, we show that anti-CD40/CpG treatment led to upregulation of T cell activat

96 e efficacy, costimulatory blockade with anti-CD40 monoclonal antibody (2C10R4) may inhibit the induct

97 trials with checkpoint inhibitors, with anti-CD40 to yield tumor-specific CD8 T cells, and with antic

98 The combined treatment with anti-CD40/CpG + IC/anti-CTLA-4 reduced T regulatory cells in

99 zed that activation of macrophages with anti-CD40/CpG, and NK cells with IC, would cause innate tumor

100 ization of engaged immune receptors, such as CD40, with RAB7 small GTPase on mature endosomes, in add

101 ation and thrombus formation, involving both CD40-dependent and -independent mechanisms.

102 potential between soluble and membrane-bound CD40 agonists.

103 enovirus encoding a chimeric, membrane-bound CD40 ligand (ISF35).

104 ; inhibition of tyrosine-protein kinase BTK; CD40 ligand blockade; interfering with the presentation

105 Upon activation by CD40 or TLR signaling, B lymphocytes activate NF-kappaB

106 tch recombination by IL-21 was attenuated by CD40 signaling, whereas IgG1 class switch recombination

107 foreign agonists, and is further enhanced by CD40-CD40L interactions between DC1 and CD4(+) T lymphoc

108 iquitous TNFRSF receptor(s) cross-linking by CD40 and Fas agonistic antibodies resulted in dose-limit

109 th facilitating T-cell chemotaxis and CD137L/CD40 induced NF-kappaB/PCAF activation.

110 Although stimulation of CD137L/CD40-mediated signaling is vital, inflammatory cytokines

111 ependent NKG2D ligand induction, this CD137L/CD40-mediated signaling activation was associated with e

112 In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunom

113 eeks after last vaccination) including CD19, CD40, and FCRL2-5 activation along with increased B cell

114 t CD10), a B-cell immunophenotype (CD19/CD20/CD40(+)), IgD and/or IgM expression (67%), and lack of p

115 HLA-DR, CD3, CD28, CD40 and CD 138 significantly increased with food reintr

116 stry/immunofluorescence for CD1a, CD3, CD28, CD40, CD69, CD80, CD138, CXCR3 and HLA-DR was performed.

117 he APC-T-cell interface (eg, CD80/CD86-CD28, CD40-CD40L, OX40L-OX40, CD155/CD112-DNAM-1) and subseque

118 monomeric CD40L and generate integrin-CD40L-CD40 ternary complex.

119 s (TRAFs) plays key roles in mediating CD40L-CD40 signaling.

120 t patients reveal the critical role of CD40L-CD40 interaction for the function of T, B, and dendritic

121 ect contact with myeloid cells through CD40L-CD40 interaction and IFN-gamma release.

122 ntly of neurotrophins, disruption of a CD40L/CD40 autocrine loop impaired early neurotrophin-promoted

123 ignatures with CD4(+) Tfh, and require CD40L/CD40 and TCR/MHCI interactions to deliver help to B cell

124 h the frequency of activated B cells (CD86(+)CD40(+)) reduced compared with pre-ART levels (p = 0.000

125 ious study on the alteration by pLL of CD86, CD40, IL-10, and IL-12 responses to LPS in BMDC; however

126 We examined the effects of endothelial cell CD40 on Toxoplasma gondii invasion of the retina and bra

127 The protective effect of endothelial cell CD40 was not explained by changes in cellular or humoral

128 ility to CD40 killing, while in normal cells CD40 signalling is cytoprotective.

129 rs with specific binding affinity to chicken CD40 extra domain (chCD40ED).

130 Direct stimulation of complex component CD40 on DCs leads to activation of Akt1, suggesting CD40

131 /CD40 fusion protein conferring constitutive CD40 signaling under control of the DC-specific CD11c pr

132 significantly higher levels of costimulatory CD40 and CD86.

133 immunodepression favoring cryptosporidiosis (CD40 ligand deficiency [n = 1], human immunodeficiency v

134 ands and adhesion molecules, including CSF2, CD40, PD-L1/PD-L2, and VCAM1.

135 lls, with stimulation via the BCR decreasing CD40-mediated IL-10 production.

136 40L reverse signalling later in development, CD40-Fc, which activates reverse signalling, had no effe

137 Dual CD40-TLR4 activation within a single tumor is thus an ap

138 We observed that dual CD40-TLR4 stimulation within a single tumor restored PD-

139 cative of DC activation and maturation, i.e. CD40, CD86, and MHC class II.

140 structural requirements needed for efficient CD40-CD40L inhibition, and serve to guide the search for

141 These vaccines bind to either CD40 or LOX-1, two dendritic cell surface receptors with

142 HIV-1 envelope protein (Env gp140) to either CD40 or LOX-1, two endocytic receptors on dendritic cell

143 d serum concentrations of IL-12 and elevated CD40 expression on CD11c(+) dendritic cells (DCs).

144 mmatory stimuli led to increased endothelial CD40 expression, at least in part due to decreased miR-4

145 microRNA mediated suppression of endothelial CD40 expression.

146 CD4(+) conventional T cells showed enhanced CD40 expression and IL-12 secretion compared with DCs co

147 were reduced if endothelial cells expressed CD40.

148 ter T. gondii infection, mice that expressed CD40 restricted to endothelial cells exhibited diminishe

149 We generated rAd5 constructs expressing CD40-targeted S1 fusion protein (rAd5-S1/F/CD40L), untar

150 Finally, CD40 signalling in cDC1 was critical not only for CD8(+)

151 d CSR in TRAF3-deficient B cells but not for CD40-induced or LPS-induced CSR, suggesting that TRAF3 r

152 These findings reveal a key role for CD40 and CD70 signaling in cDC1s and have major implicat

153 ign free of chemo- or radiotherapy, we found CD40 activation with agonistic antibodies (aCD40) produc

154 pically similar population of CD4(+) Foxp3+, CD40 ligand-positive T cells was found in diseased liver

155 bled translocation of the TRAF2 complex from CD40 to the cytoplasm.

156 e BCR in the absence of costimulation (e.g., CD40) does not induce CSR; thus, it remains elusive whet

157 It remains undetermined whether and how CD40 on DCs impacts the pathogenesis of atherosclerosis.

158 However, CD40 did not cause TNF-alpha or IL-1beta secretion in Mu

159 Iscalimab is a fully human, CD40 pathway blocking, nondepleting monoclonal antibody

160 mmation, pulmonary DC recruitment and MHC-II/CD40 expression leading to diminished Th1/17 but unchang

161 in affording protection from HIV.IMPORTANCE CD40-CD40 ligand (CD40L) interaction is crucial for indu

162 cytes triggered Hsp70-dependent autophagy in CD40(+) endothelial cells and anti-T. gondii activity de

163 mCD40L to also directly induce cell death in CD40-expressing carcinomas, subsequently releasing tumou

164 rotid artery wire injury reduces markedly in CD40(-/-) apolipoprotein E-deficient (apoE(-/-)) mice bu

165 of CD40L, and this plays a critical role in CD40/CD40L signaling.

166 icient (apoE(-/-)) mice but only slightly in CD40 ligand(-/-)apoE(-/-) mice, compared with apoE(-/-)

167 l cerebral malaria mortality and symptoms in CD40-KO recipients, indicating platelets elicit pathogen

168 ear if alpha5beta1 and CD40 work together in CD40/CD40L signaling or how alpha5beta1 binds to CD40L.

169 5, a potent growth factor for ILC3s, induced CD40 ligand (CD40L) expression on circulating and tonsil

170 The inflammatory CD40-CD40L pathway is implicated in various autoimmune d

171 ent-resistant membrane domain and to inhibit CD40-induced phosphorylation of the kinases Lyn and prot

172 IL-35 inhibited CD40 ligand-, IL-4-, and IL-21-mediated IgE production b

173 ring endothelial cell-leukocyte interaction, CD40 restricts T. gondii invasion of neural tissue throu

174 jection of thrombin-activated platelets into CD40(-/-)apoE(-/-) mice was performed every 5 days, star

175 stemic antitumor activity after intratumoral CD40 triggering with ISF35 in combination with checkpoin

176 s, and their suppressive activities involved CD40, CD80, CD86, and intercellular adhesion molecule in

177 regulated their activation markers, that is, CD40, CD80, CD86, and MHC class II molecules.

178 ing the expansion of this population and its CD40 expression, while lowering its CD134 expression, th

179 expression of CD40LG and active full-length CD40 was increased in the disease tissues, whereas that

180 vated in response to key T cell signals like CD40 and IL-21 and that it regulated GC formation and ma

181 n engineered latent membrane protein 1 (LMP)/CD40 fusion protein conferring constitutive CD40 signali

182 Moreover, DC-LMP1/CD40 chimeras developed inflammatory bowel disease chara

183 sed by 37% and 60%, respectively, in DC-LMP1/CD40 chimeras.

184 ed, DC-LMP1/CD40/Ldlr(-/-) chimeras (DC-LMP1/CD40) showed increased antigen-presenting capacity of DC

185 l of the DC-specific CD11c promoter (DC-LMP1/CD40).

186 As expected, DC-LMP1/CD40/Ldlr(-/-) chimeras (DC-LMP1/CD40) showed increased

187 sed levels of mRNAs encoding cytokines (LTB; CD40; and tumor necrosis factor superfamily [TNFSF] memb

188 tent membrane protein 1 (LMP1) (which mimics CD40 signaling), and EBV-encoded nuclear antigen 3A (EBN

189 the avirulent strains reciprocally modulated CD40-induced Ras-mediated signaling through PI-3K and Ra

190 The costimulatory molecule CD40 is a major driver of atherosclerosis.

191 MHC class II and the costimulatory molecule CD40 on the surface of the cells.

192 vely express the immune-stimulatory molecule CD40 ligand (CD40L) and explored efficacy in different m

193 nterleukin-6 and the costimulatory molecules CD40 and inducible T cell costimulator ligand was signif

194 of cDC1s and their costimulatory molecules, CD40, CD70, and CD80/CD86, in expansion and antitumor ef

195 We developed a rat/mouse chimeric anti-mouse CD40 antagonist mAb, 201A3, and evaluated its ability to

196 tissues, whereas that of a dominant-negative CD40 isoform was decreased.

197 Constitutive activation of CD40 in DCs results in inflammation of the gastrointesti

198 0L and ICOS in SE in response to addition of CD40 and ICOSL, respectively, to SLB presenting TCR liga

199 n integrins have potential as antagonists of CD40/CD40L signaling.

200 In vivo blockade of CD40 ligand attenuated B-cell abnormalities in a mouse m

201 s have a survival defect after engagement of CD40 or Toll-like receptors (TLR), despite paradoxically

202 kin (IL)-1beta production, and expression of CD40 and CD86 were lower among ART-treated HIV-infected

203 eins on DCs, IL-21 reduced the expression of CD40 in the presence of H. pylori Also, Th17 recall resp

204 ivities were maintained due to expression of CD40 ligand on a subset of CD4(+) Foxp3+ T cells.

205 nd naive B cells to assess the expression of CD40-downstream genes in synovial tissues from anti-citr

206 efficacy required DCs and host expression of CD40.

207 ctivated platelets were abrogated by lack of CD40 on injected platelets.

208 ut this effect was also abrogated by lack of CD40 on injected platelets.

209 the BCR and CD40 or strong cross-linking of CD40 alone.

210 the extensive intracellular localization of CD40 and the strong correlation of RAB7 expression with

211 In carcinomas, the nature of CD40 ligand shapes the outcome of CD40 ligation.

212 nature of CD40 ligand shapes the outcome of CD40 ligation.

213 n, and suppress LPS-induced up-regulation of CD40 and CD86.

214 upregulation involving reverse signaling of CD40 and CD137L on tumor cells which, along with inflamm

215 teract with CD4 T cells (the major source of CD40 ligand).

216 olecular nature of the tumour specificity of CD40 signalling and explained the differences in pro-apo

217 on are linked to the blunted upregulation of CD40, a major feature of the unconventional maturation p

218 Upregulation of CD40, CD80, CD83, and CD86 on monocyte-derived dendritic

219 either major histocompatibility class II or CD40 in cDC1 impaired tumour rejection, consistent with

220 C57BL/6 donors but not from MHC class II- or CD40-deficient donors.

221 g platelets elicit pathogenesis and platelet CD40 is a key molecule.

222 Results suggest that platelet CD40 plays a pivotal role in neointima formation after a

223 cell receptor (TCR) signaling and preformed CD40 ligand mobilization to the immunological synapse, t

224 tosis is only achieved by membrane-presented CD40 ligand (mCD40L), as soluble receptor agonists are b

225 n promote plasmablast formation by providing CD40 signals to naive B cells.

226 nner mediated by the co-stimulatory receptor CD40.

227 rug engagement of a membrane bound receptor (CD40) that is critical to immune regulation in colon bio

228 The avirulent strain failed to reduce CD40 relocation to the detergent-resistant membrane doma

229 ad in the retina and brain not only required CD40 expression in endothelial cells but was also depend

230 ated H1 eviction for induction of the silent CD40 gene and further demonstrates that H1 eviction, see

231 Soluble CD40 ligand (sCD40L) has been implicated in the developm

232 0.005), IL-1beta (0.615, p<0.05) and soluble CD40 ligand (0.868, p<0.005), and CSF levels of IL-10 (0

233 in vitro effects of rhIFN-gamma and soluble CD40 ligand (sCD40L) treatment on macrophages.

234 e chemotactic protein-1 (MCP-1), and soluble CD40 ligand were also observed in the experimental group

235 ombomodulin, soluble P-selectin, and soluble CD40 ligand, as well as coagulation factors, endogenous

236 m Cd40(-/-) mice and were rescued by soluble CD40.

237 ombinatorial treatment incorporating soluble CD40 agonist and pharmacological inhibition of Trx-1 was

238 antitumor efficacy and induced TT-specific, CD40 ligand-expressing CD4(+) T helper cells and maturat

239 Strikingly, CD40 activation resulted in down-regulation of Thioredox

240 DCs leads to activation of Akt1, suggesting CD40 involvement in anti-apoptotic effects observed.

241 compromised- SCID or inducible NO synthase-, CD40-, or IL-12-deficient mice, indicating attenuation.

242 Unlike CD180 targeting, CD40 targeting only induced DCs but not B cells to becom

243 We found that CD40 is closely regulated by miR-424 and miR-503, which

244 ed bone marrow chimeric mice identified that CD40 and CD70 but not CD80/CD86 signaling in cDC1s playe

245 Our studies indicate that CD40 in Muller cells is sufficient to upregulate retinal

246 immunofluorescence analyses, we report that CD40 ligation elicits TANK-binding kinase 1 (TBK1)-media

247 Here we show that CD40, a member of the TNF receptor superfamily, is a maj

248 These results suggest that CD40 forward signalling is a novel physiological regulat

249 These results suggest that CD40-activated CD40L reverse signalling has striking and

250 ceptional therapeutic efficacy suggests that CD40 is a central disease pathway in murine SLE.

251 Results from previous studies support that CD40 protein expression is elevated in Muller glia of di

252 The CD40 decoy receptor, sCD40R, may serve as a potential th

253 The CD40 receptor exists in a soluble form, sCD40R, and has

254 The CD40/CD40 ligand dyad in endothelial cells (EC) has a ce

255 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway.

256 healthy volunteers, the balance between the CD40 and B-cell receptor (BCR) signalling modulated IL-1

257 CD40 agonists bind the CD40 molecule on antigen-presenting cells and activate t

258 s, administering novel agents that block the CD40/CD154 costimulation pathway, such as an anti-CD40 m

259 s, our results provide new insights into the CD40 signaling mechanisms whereby Ser-11 phosphorylation

260 ckade of CXCL13 as well as inhibition of the CD40 ligand and the ICOS ligand suppressed DSA productio

261 ctors in combination with stimulation of the CD40 pathway in the mouse cancer model boosted cytotoxic

262 mab appears to be a promising blocker of the CD40-CD154 costimulatory pathway with potential use in t

263 on of novel small-molecule inhibitors of the CD40-CD40L interaction designed starting from the chemic

264 The safety and efficacy of the CD40-targeted vaccine justify further development for fu

265 Here, we studied the CD40 pathway as an alternative bridge between dendritic

266 ograft survival induced by CoB targeting the CD40-CD154 pathway.

267 onclusion, our data suggest that therapeutic CD40-CD40L blocking agents may prove efficacious not onl

268 tumor immune escape via antigen loss through CD40/CD40L-mediated cytotoxicity and induction of a sust

269 ike tyrosine kinase 3 ligand (Flt3L) and TLR/CD40 agonists augmented expansion of adoptively transfer

270 We found that TLR/CD40-mediated expansion and antitumor efficacy of adopti

271 odulation with Flt3L, radiotherapy, and TLR3/CD40 stimulation induces an influx of stem-like Tcf1(+)

272 Several agonists to CD40 have shown to induce acquired immune responses.

273 at one of these 48 proteins, C4BPA, binds to CD40 of placental villous trophoblast to activate p100 p

274 necrosis factor (TNF) superfamily, binds to CD40, leading to many effects depending on target cell t

275 ild-type CD40L; however, they still bound to CD40.

276 L cells fully resistant to venetoclax due to CD40-mediated induction of Bcl-XL, Mcl-1, and Bfl-1.

277 Overall, targeting Env to CD40 gave more robust T cell and serum antibody response

278 g to alpha5beta1 and alphavbeta3 (but not to CD40), suggesting that the defect in integrin binding ma

279 cation, adoptive transfer of WT platelets to CD40-KO mice, which are resistant to experimental cerebr

280 tive transfer of wild-type (WT) platelets to CD40-KO mice, which do not control parasite replication,

281 h coincides with increased susceptibility to CD40 killing, while in normal cells CD40 signalling is c

282 the material so that these cannot upregulate CD40 in full in response to LPS.

283 atched healthy volunteers were activated via CD40 and BCR, either alone or in combination.

284 y B cells, helper T cells act on B cells via CD40 ligand and secreted cytokines that guide Ig class s

285 vaccines, but especially that delivered via CD40, raised robust immunity against HIV-1 as measured b

286 excess RGD proteins, including vitronectin, CD40-ligand and thrombospondin-1.

287 DCs but was not required on B cells, whereas CD40 was required on B cells but not on DCs in the gener

288 ls were provided early in infection, whereas CD40/CD40L help was provided late in infection.

289 ers survival and antibody secretion, whereas CD40 costimulation with IL-21 or IFN-gamma promotes a T-

290 , the simultaneous use of IL-6 blockade with CD40 stimuli may tilt the tumor microenvironment to prom

291 interaction of virion-associated CD40L with CD40 on B cells.

292 A) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and im

293 everal different isotypes after culture with CD40 ligand and IL-4.

294 mice (8 to 10 weeks old) were cultured with CD40 ligand (CD40L) and the Toll-like receptor 9 (TLR9)

295 early DRG targets and was co-expressed with CD40 in early DRG neurons.

296 During diabetes, mice with CD40 expressed in Muller cells upregulated retinal tumor

297 Using mice with CD40 expression restricted to Muller cells, we identifie

298 cted in Muller cells from diabetic mice with CD40(+) Muller cells.

299 ing with this, combining BCR signalling with CD40 ligation did not reduce IL-10 secretion as was obse

300 Yet, combination therapy with CD40 agonist and Flt3 ligand restores cDC1 abundance to